Renal cancer studies at Providence Cancer Institute
October 30, 2017
T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. At Providence Cancer Institute, several clinical trials of these novel approaches are now open to patients with renal cancer, including two studies comparing the effectiveness of different combinations of targeted therapies and immunotherapies:
Both of these studies are led by Brendan Curti, M.D., director of Genitourinary Oncology Research at the Robert W. Franz Cancer Center. Dr. Curti contributed to the clinical development of nivolumab (Opdivo) for renal cancer, a treatment that was recently approved by the FDA.
Making progress in immunotherapy
One of the first applications of immunotherapy in cancer medicine was the use of high-dose interleukin-2 (IL-2) in patients with renal cancer. Providence Cancer Institute is the largest IL-2 program in Oregon offering this treatment to patients with metastatic kidney cancer, and is among the top five nationwide.
Our research team focuses on developing new immunotherapy approaches, as well as new ways to improve responses to IL-2, including an ongoing study of IL-2 combined with SBRT (stereotactic body radiation therapy).
New studies are added frequently. For a complete list of all current studies, please visit our website. For more information, call 503-215-2614.